FDA Approves LIRAGLUTIDE — Biocon Pharma Inc.

# FDA Approves Generic Liraglutide from Biocon Pharma Inc. Biocon Pharma Inc. has received FDA approval for its generic formulation of liraglutide (ANDA215245), a widely-prescribed subcutaneous GLP-1 receptor agonist, potentially expanding affordable treatment options in the competitive diabetes and weight-management markets. The approval could increase price competition in the liraglutide segment, though branded alternatives and newer GLP-1 agents continue to dominate market share among both physicians and patients.